Anti-Nicotinic Acetylcholine Receptor beta antibody [B3] (ab11150)

Overview

  • Product name
    Anti-Nicotinic Acetylcholine Receptor beta antibody [B3]
    See all Nicotinic Acetylcholine Receptor beta primary antibodies
  • Description
    Mouse monoclonal [B3] to Nicotinic Acetylcholine Receptor beta
  • Specificity
    Ab11150 binds human AChR Beta subunit. Exhibits homogenous, high avidity binding to the receptor. Binding to recombinant beta subunit demonstrated on Western blotting.
  • Tested applications
    Suitable for: Flow Cyt, IHC-Fr, WB, IPmore details
  • Species reactivity
    Reacts with: Human
    Does not react with: Mouse, Rat, Chicken
  • Immunogen

    Full length protein (Human).

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Storage buffer
    Preservative: 0.09% Sodium Azide
    Constituents: PBS
  • Concentration information loading...
  • Purity
    Protein G purified
  • Clonality
    Monoclonal
  • Clone number
    B3
  • Myeloma
    NS1
  • Isotype
    IgG1
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab11150 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt 1/1. ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
IHC-Fr 1/3.
WB 1/100. Predicted molecular weight: 60.1 kDa.
IP 1/100.

Target

  • Function
    After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
  • Involvement in disease
    Defects in CHRNB1 are a cause of congenital myasthenic syndrome slow-channel type (SCCMS) [MIM:601462]. SCCMS is the most common congenital myasthenic syndrome. Congenital myasthenic syndromes are characterized by muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. SCCMS is caused by kinetic abnormalities of the AChR, resulting in prolonged endplate currents and prolonged AChR channel opening episodes.
    Defects in CHRNB1 are a cause of congenital myasthenic syndrome with acetylcholine receptor deficiency (ACHRDCMS) [MIM:608931]. ACHRDCMS is a post-synaptic congenital myasthenic syndrome. Mutations underlying AChR deficiency cause a 'loss of function' and show recessive inheritance.
  • Sequence similarities
    Belongs to the ligand-gated ion channel (TC 1.A.9) family. Acetylcholine receptor (TC 1.A.9.1) subfamily. Beta-1/CHRNB1 sub-subfamily.
  • Cellular localization
    Cell junction > synapse > postsynaptic cell membrane. Cell membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Acetylcholine receptor protein beta chain precursor antibody
    • Acetylcholine receptor subunit beta antibody
    • ACHB_HUMAN antibody
    • AChR antibody
    • ACHRB antibody
    • Cholinergic receptor nicotinic beta polypeptide 1 (muscle) antibody
    • Chrnb 1 antibody
    • CHRNB antibody
    • chrnb1 antibody
    • CMS1D antibody
    • CMS2A antibody
    • Nicotinic acetylcholine receptor beta subunit precursor antibody
    • SCCMS antibody
    see all

References

ab11150 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab11150.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up